133 related articles for article (PubMed ID: 1729534)
1. An investigation of factors influencing the in vitro induction of LAK activity against a variety of human bladder cancer cell lines.
Jackson AM; Hawkyard SJ; Prescott S; Ritchie AW; James K; Chisholm GD
J Urol; 1992 Jan; 147(1):207-11. PubMed ID: 1729534
[TBL] [Abstract][Full Text] [Related]
2. LAK-cell-mediated cytotoxicity against tumor cell targets used to monitor the stimulatory effect of interleukin-2: cytotoxicity, target recognition and phenotype of effector cells lysing the Daudi, T24 and K562 tumor cell lines.
Hermann GG; Zeuthen J; Claësson MH
Nat Immun; 1992; 11(1):7-16. PubMed ID: 1611282
[TBL] [Abstract][Full Text] [Related]
3. Cellular cytotoxicity of human natural killer cells and lymphokine-activated killer cells against bladder carcinoma cell lines.
Wang MH; Flad HD; Böhle A; Chen YQ; Ulmer AJ
Immunol Lett; 1991 Mar; 27(3):191-7. PubMed ID: 2060970
[TBL] [Abstract][Full Text] [Related]
4. Dissecting the immunobiological effects of Bacillus Calmette-Guérin (BCG) in vitro: evidence of a distinct BCG-activated killer (BAK) cell phenomenon.
Böhle A; Thanhäuser A; Ulmer AJ; Ernst M; Flad HD; Jocham D
J Urol; 1993 Dec; 150(6):1932-7. PubMed ID: 8230540
[TBL] [Abstract][Full Text] [Related]
5. Intercellular adhesion molecule-1 expression by bladder cancer cells: functional effects.
Campbell SC; Tanabe K; Alexander JP; Edinger M; Tubbs RR; Klein EA
J Urol; 1994 May; 151(5):1385-90. PubMed ID: 7908992
[TBL] [Abstract][Full Text] [Related]
6. Induction of bacillus-Calmette-Guérin-activated killer cells from human peripheral blood mononuclear cells against human bladder carcinoma cell lines in vitro.
Thanhäuser A; Böhle A; Flad HD; Ernst M; Mattern T; Ulmer AJ
Cancer Immunol Immunother; 1993 Jul; 37(2):105-11. PubMed ID: 8319241
[TBL] [Abstract][Full Text] [Related]
7. Reduced LAK cytotoxicity of peripheral blood mononuclear cells in patients with bladder cancer: decreased LAK cytotoxicity caused by a low incidence of CD56+ and CD57+ mononuclear blood cells.
Hermann GG; Petersen KR; Steven K; Zeuthen J
J Clin Immunol; 1990 Nov; 10(6):311-20. PubMed ID: 1707414
[TBL] [Abstract][Full Text] [Related]
8. Modulation by cis-diamminedichloroplatinum (II) of the susceptibilities of human T24 lined and freshly separated autologous urinary bladder transitional carcinoma cells to peripheral blood lymphocytes and lymphokine activated killer cells.
Mizutani Y; Nio Y; Yoshida O
J Urol; 1992 Feb; 147(2):505-10. PubMed ID: 1732632
[TBL] [Abstract][Full Text] [Related]
9. Cytotoxicity of interleukin 2-induced lymphokine-activated killer (LAK) cells against human leukemia and augmentation of killing by interferons and tumor necrosis factor.
Teichmann JV; Ludwig WD; Thiel E
Leuk Res; 1992; 16(3):287-98. PubMed ID: 1560676
[TBL] [Abstract][Full Text] [Related]
10. Role of adhesion molecules in lymphokine-activated killer cell killing of bladder cancer cells: further evidence for a third ligand for leucocyte function-associated antigen-1.
Jackson AM; Alexandrov AB; Prescott S; James K; Chisholm GD
Immunology; 1992 Jun; 76(2):286-91. PubMed ID: 1353063
[TBL] [Abstract][Full Text] [Related]
11. Natural killer (NK) and lymphokine-activated killer (LAK) activities in a patient who recovered from cancer, and the characteristics of LAK cells generated from CD4-CD8- and CD8+ peripheral blood lymphocytes.
Komatsu F; Kihara K
Clin Immunol Immunopathol; 1995 Oct; 77(1):75-81. PubMed ID: 7554487
[TBL] [Abstract][Full Text] [Related]
12. Interleukin-7 induces differential lymphokine-activated killer cell activity against human melanoma cells, keratinocytes, and endothelial cells.
Schadendorf D; Böhm M; Möller P; Grünewald T; Czarnetzki BM
J Invest Dermatol; 1994 Jun; 102(6):838-42. PubMed ID: 8006445
[TBL] [Abstract][Full Text] [Related]
13. Cytokines alter target cell susceptibility to lysis: I. Evaluation of non-major histocompatibility complex-restricted effectors reveals differential effects on natural and lymphokine-activated killing.
Wiebke EA; Custer MC; Rosenberg SA; Lotze MT
J Biol Response Mod; 1990 Apr; 9(2):113-26. PubMed ID: 2111373
[TBL] [Abstract][Full Text] [Related]
14. Susceptibility of human leukemia to allogeneic and autologous lymphokine-activated killer cell activity: analysis of 252 samples.
Teichmann JV; Ludwig WD; Thiel E
Nat Immun; 1992; 11(3):117-32. PubMed ID: 1392400
[TBL] [Abstract][Full Text] [Related]
15. Bacillus Calmette-Guérin sensitises fresh transitional carcinoma cells and T24 cell line to non-MHC-restricted cytotoxicity in vitro.
Kaasinen ES; Kalliomäki PH; Alfthan OS; Timonen TT
Br J Urol; 1993 Dec; 72(6):897-906. PubMed ID: 8306153
[TBL] [Abstract][Full Text] [Related]
16. Suppression of lymphokine-activated killer (LAK) cell induction mediated by interleukin-4 and transforming growth factor-beta 1: effect of addition of exogenous tumour necrosis factor-alpha and interferon-gamma, and measurement of their endogenous production.
Brooks B; Chapman K; Lawry J; Meager A; Rees RC
Clin Exp Immunol; 1990 Dec; 82(3):583-9. PubMed ID: 2124961
[TBL] [Abstract][Full Text] [Related]
17. Resistance of different tumor cells to lysis by lymphokine activated killer cells can be mediated by distinct mechanisms.
Bean P; Mazumder A
Immunobiology; 1992 Jun; 185(1):63-77. PubMed ID: 1398742
[TBL] [Abstract][Full Text] [Related]
18. Suramin inhibits tumor cell cytotoxicity mediated through natural killer cells, lymphokine-activated killer cells, monocytes, and tumor necrosis factor.
LaPushin R; Totpal K; Higuchi M; Aggarwal BB
J Clin Immunol; 1994 Jan; 14(1):39-49. PubMed ID: 8132736
[TBL] [Abstract][Full Text] [Related]
19. Effects of bacillus Calmette-Guerin on cytotoxic activities of peripheral blood lymphocytes against human T24 lined and freshly isolated autologous urinary bladder transitional carcinoma cells in patients with urinary bladder cancer.
Mizutani Y; Nio Y; Fukumoto M; Yoshida O
Cancer; 1992 Jan; 69(2):537-45. PubMed ID: 1728384
[TBL] [Abstract][Full Text] [Related]
20. Augmentation of the lymphokine-activated killer cell response in head and neck cancer patients by combination interleukin-2 and interferon-alpha.
Wanebo H; Blackinton D; Weigel T; Turk P; Mehta S
Am J Surg; 1991 Oct; 162(4):384-7. PubMed ID: 1951894
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
